Literature DB >> 8367021

Chronic methanesulfonyl fluoride enhances one-trial per day reward learning in aged rats.

D H Malin1, R E Plotner, S J Radulescu, R N Ferebee, J R Lake, P G Negrete, P J Schaefer, M K Crothers, D E Moss.   

Abstract

Aged (24-month-old) rats were treated chronically with methanesulfonyl fluoride (MSF), an acetylcholinesterase (AChE) inhibitor with selectivity for central nervous system AChE, or with injection vehicle alone. Twelve 0.22 mg/kg IP injections were given over 4 weeks. MSF rats showed significantly greater speed and accuracy on a 1 trial/day discriminative reward learning task. The chronic MSF treatment resulted in a 56% decrease in brain AChE activity but no discernable locomotor side effects and no liver damage as indicated by aspartate transferase activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8367021     DOI: 10.1016/0197-4580(93)90127-w

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  3 in total

1.  Cholinesterase Inhibitor Therapy in Alzheimer's Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates.

Authors:  Donald E Moss; Ruth G Perez; Haruo Kobayashi
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

2.  A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease.

Authors:  Donald E Moss; Ruggero G Fariello; Jörg Sahlmann; Isabel Sumaya; Federica Pericle; Enrico Braglia
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

Review 3.  Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Are Irreversible Inhibitors the Future?

Authors:  Donald E Moss
Journal:  Int J Mol Sci       Date:  2020-05-13       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.